Navigation Links
Neuralstem Completes Phase Ia in Neuroregenerative Small Molecule Drug, NSI-189, Major Depressive Disorder Trial
Date:10/27/2011

essive disorder.  The Phase Ib portion of the trial, in depressed patients, is expected to commence later this year. Additional indications could include schizophrenia, Alzheimer's disease and bipolar disorder.

For up-to-date information on the clinical trials for NSI-189/MDD, ALS and other Neuralstem cell therapy and pharmaceutical treatments in development, visit www.neuralstem.com

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2010 and the quarterly report on Form 10-Q for the period ended June 30, 2011.


'/>"/>
SOURCE Neuralstem, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Neuralstem Announces Issuance of Core Technology Patent in Europe
2. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
3. Neuralstems ALS Trial on Clinical Hold
4. Neuralstems Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
5. Neuralstem Receives FDA Approval to Commence Drug Trial for Major Depression
6. Neuralstem Receives FDA Orphan Designation for Spinal Cord Stem Cells for Treatment of ALS
7. Neuralstem Updates ALS Clinical Trial Progress
8. Dr. Eva Feldman, Principal Investigator, Presents Interim Safety Results for Neuralstem ALS Trial
9. Neuralstem Updates NSI-189 Major Depression Trial
10. Neuralstem Announces Notice of Allowance for Two Additional Neurogenic Compound Patents
11. Dr. Eva Feldman, Principal Investigator, Presents Interim Data on Neuralstem ALS Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... -- TODAY, AEGATE, the leader in medicine ... appointment of Peter Fox as Chief Technology ... Partner Officer. Peter has served as Development ... by Oracle in 2011. Prior to Datanomic, ... and subsequently Convergys, a world renowned billing system ...
(Date:12/19/2014)... 19, 2014 Breckenridge Pharmaceutical, Inc. announced today ... MSN Laboratories Pvt. Ltd. ( Hyderabad, India ... several new ANDAs.  Under the terms of the agreement, ... to Breckenridge for the U.S. market, and Breckenridge will ... and MSN have agreed to develop an oral antibiotic ...
(Date:12/19/2014)... Colo. , Dec. 19, 2014  Monarch America ... Cannabis Kinetics Corp.) is pleased to provide this review ... continued growth in 2015. "Over this past ... goals and I am extremely proud to say that ... position today than it has ever been," stated ...
Breaking Medicine Technology:Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 2Monarch America Inc. CEO Reviews Recent Achievements and Provides Outlook for 2015 3
(Date:12/22/2014)... (PRWEB) December 22, 2014 Physicians in ... (rituximab) for the treatment of non-Hodgkin’s lymphoma (NHL), according ... a leading global healthcare consulting firm. MabThera is the ... (DLBCL), the most common form of NHL. , According ... and Barriers,” the incidence of NHL in China has ...
(Date:12/22/2014)... 22, 2014 Give a loved one ... gift of health and vitality. , For a limited ... top-selling anti-aging formulas in special Holiday Wellness gift packages ... , Each bottle contains cutting-edge, proven nutritional support ... work as well as we age. , ...
(Date:12/22/2014)... Austin, Texas (PRWEB) December 22, 2014 ... hustle and bustle of Black Friday shopping and opted ... publishing and marketing education company, for their 5th annual ... Marketer charged just $7 to attend the 5 ... sales that they promptly donated to support two Central ...
(Date:12/22/2014)... 2014 NAPW honors ... of the Year. She is recognized with this prestigious ... recognized networking organization of professional women in the country, ... of Professional Women is a vibrant networking community with ... Ms. Kreider is passionate and committed to best practices ...
(Date:12/21/2014)... December 22, 2014 In this ... segmented by power source, product, and application. The ... battery-powered, and pneumatic instruments. By product, the market ... accessories segments. The handpieces market is further subdivided ... suction coagulators, laparoscopic instruments, shavers, wire/pin drivers, and ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... Oklahoma Health Sciences Center has proven that a new drug ... in the prevention of blood clots following hip replacement surgery. ... the formation of blood clots in the deep veins of ... (DVT). The blood clots become life-threatening pulmonary embolisms (PE) when ...
... joined the Greening the Operating Room (GOR) Initiative, Practice ... and prescriptive path to green the country,s operating rooms. ... awareness of the huge contribution made by operating rooms ... 30 percent of a hospital,s total waste. Dartmouth-Hitchcock ...
... and Brigham and Women,s Hospital have shown that they can ... in a form that has been encapsulated in a nanoparticle ... reaches its target. Using the new particles, the researchers ... one-third the amount of conventional cisplatin needed to achieve the ...
... , TUESDAY, Jan. 11 (HealthDay News) -- After a ... "special," today,s young people crave these boosts to their ... research suggests. The self-esteem movement of recent decades ... and praise in a world that won,t necessarily cooperate ...
... as to whether interstitial brachytherapy has advantages compared to other ... newer studies provide proof in this respect. This is the ... and Efficiency in Health Care (IQWiG) on 11 January 2011. ... findings of research already completed in 2007. However, it was ...
... in Spanish . , The work carried out ... an electronic architecture for gamma ray detectors to industry transfer ... through experimental studies at the Gregorio Maran Hospital. The ... and Manuel Desco, from the Department of de Bioengineering and ...
Cached Medicine News:Health News:International research team reports major findings in prevention and treatment of blood clots 2Health News:Dartmouth-Hitchcock joins effort to green nation's operating rooms 2Health News:Delivering a potent cancer drug with nanoparticles can lessen side effects 2Health News:Delivering a potent cancer drug with nanoparticles can lessen side effects 3Health News:For College Students, Praise May Trump Sex and Money 2Health News:For College Students, Praise May Trump Sex and Money 3Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 2Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 3Health News:Benefit of brachytherapy in patients with early-stage prostate cancer is still unclear 4Health News:New molecular imaging technologies for detecting cellular processes 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: